Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 15, 2023
Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative studyTatsuki Miyamoto, Makito Miyake, Tomonori Nakahama, et al.
Methods and Protocols|August 28, 2024
A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE TrialMakito Miyake, Satoshi Anai, Yusuke Iemura, et al.
World Journal of Urology|March 21, 2024
Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysisNobutaka Nishimura, Makito Miyake, Kota Iida, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 13, 2021
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomyNobutaka Nishimura, Makito Miyake, Kota Iida, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2025
Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancerMakito Miyake, Takuya Owari, Kota Iida, et al.
Japanese Journal of Clinical Oncology|December 7, 2023
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohortMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
BMC Cancer|March 12, 2021
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative studyMakito Miyake, Kota Iida, Nobutaka Nishimura, et al.
Cancers|April 12, 2022
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective StudyTakuto Shimizu, Makito Miyake, Nobutaka Nishimura, et al.
International Journal of Clinical Oncology|June 18, 2024
Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohortMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Pageof 6